Form 497 Innovator ETFs Trust

 

Rule 497(e)

File No. 333-146827

 

Innovator ETFs^® Trust

(the “Trust”)

 

Innovator U.S. Equity Buffer ETFÔ – February

Innovator U.S. Equity Power Buffer ETFÔ – February

Innovator U.S. Equity Ultra Buffer ETFÔ – February

(each, a “Fund” and together, the “Funds”)

 

Supplement To Each Fund’s Prospectus
Dated February 27, 2024

 

January 24, 2025

 

As described in detail in each Fund’s prospectus, an investment in shares of a Fund is subject to an upside return cap (the “Cap”) that represents the maximum percentage return an investor can achieve from an investment in the Fund for the Outcome Period of approximately one year. The current Outcome Period for each Fund will end on January 31, 2025, and each Fund will commence a new Outcome Period that will begin on February 1, 2025 and end on January 31, 2026. Each Fund’s Cap will not be determined until the start of the new Outcome Period on February 1, 2025. A supplement to each Fund’s prospectus will be filed on January 31, 2025 that will include the actual Cap for the new Outcome Period, which may be higher or lower than the estimated Cap ranges set forth below. As of January 24, 2025, the expected range of each Fund’s Cap is set forth below.

 

Fund Name	Ticker	Estimated Cap Range
Innovator U.S. Equity Buffer ETFÔ – February	BFEB	14.21% – 16.21% (13.42% – 15.42% after taking into account the Fund’s unitary management fee)
Innovator U.S. Equity Power Buffer ETFÔ – February	PFEB	10.84% – 12.59% (10.05% – 11.80% after taking into account the Fund’s unitary management fee)
Innovator U.S. Equity Ultra Buffer ETFÔ – February	UFEB	10.69% – 12.44% (9.90% – 11.65% after taking into account the Fund’s unitary management fee)

 

Please Keep This Supplement With Your Prospectus For Future Reference

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ORIX Submits Form 20-F for Filing for the Fiscal Year Ended March 31, 2026
• CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
• AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation